Navigation Links
Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
Date:11/17/2010

tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
2. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
3. Dendreon Announces Change in Board of Directors
4. Dendreon Announces Election of Dr. David C. Stump to Board of Directors
5. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
6. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
7. Dendreon Announces Pricing of Common Stock Offering
8. Dendreon Appoints Hans Bishop as Chief Operating Officer
9. Dendreon Announces Proposed Public Offering of Common Stock
10. Dendreon Receives FDA Acknowledgement of Complete Response
11. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Beckman Coulter , a global ... has renewed its agreement with Personify for ... agreement, Personify will continue to streamline the Beckman Coulter ... analytics, including time-to-fill, time-to-source and a deep reduction to ... Personify was based on the success of our partnership ...
(Date:9/17/2014)... 2014 NASA’s MESSENGER has just celebrated ... is proud to have one of its latch valves, ... is a scientific investigation of the planet Mercury. It ... there, and has provided a vast amount of information ... of latch valves utilize solenoids that also include permanent ...
(Date:9/16/2014)... “Nature has developed, very cleverly, some ... desire in optical design,” said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we’ll ... in San Diego in August during a conference called ... chaired by Shaw and Rongguang Liang of the University ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
Breaking Biology Technology:Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2
... HUBBARD, Ohio, Jan. 8 NanoLogix, Inc. (OTC:,NNLX), ... the company,has been named "Stock Pick of January ... vice president, stated,that "This is another example of ... We are happy to be selected by Stockprowler,-- ...
... 1 Clinical Trial -, MADISON, Wis., Jan. 8 ... develops products to detect,treat and monitor human cancers, today ... offering. Cellectar will use the money to continue,operations and ... oncology,product candidate, CLR1404, which is planned to start this ...
... strengthen Elekta,s offering and accelerate the company,s expansion into ... high growth ... (publ) (STO: EKTAb),a world leader in clinical solutions for radiation ... based on,a Letter of Intent to acquire CMS Inc. for ...
Cached Biology Technology:NanoLogix, Inc. Makes Stock Pick List 2Cellectar, Inc. Raises $13 Million in Private Offering 2Cellectar, Inc. Raises $13 Million in Private Offering 3Elekta Negotiates To Acquire CMS 2Elekta Negotiates To Acquire CMS 3Elekta Negotiates To Acquire CMS 4Elekta Negotiates To Acquire CMS 5
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... Environmental Health at the Mailman School of Public Health ... asthma and prenatal exposure to two phthalates used in ... in the journal Environmental Health Perspectives . ... higher levels of the chemicals, butylbenzyl phthalate (BBzP) and ... percent increase in risk of developing asthma between age ...
(Date:9/16/2014)... Menopause Society (NAMS) has published its key, evidence-based ... everything from hot flashes to heart disease. The ... for Clinical Care of Midlife Women," was published ... . This is the first, comprehensive set of ... freely available to all clinicians who care for ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... -- In the summer of 1968, a new strain of ... spread around the globe and eventually killed an estimated 1 ... there are many strains of H3N2 circulating in birds and ... have the potential to generate a pandemic if they leap ...
... from the David Geffen School of Medicine at UCLA have ... of Sciences in recognition of their distinguished and continuing achievements ... is considered one of the highest honors presented to scientists ... Thomas Edison, Orville Wright and Alexander Graham Bell. ...
... a new door to developing drugs to slow the ... Edward A. Fon at the Montreal Neurological Institute and ... in the Department of Biochemistry at the Faculty of ... Parkin. Mutations in Parkin cause a rare hereditary form ...
Cached Biology News:Potential flu pandemic lurks 2Potential flu pandemic lurks 32 UCLA faculty elected to National Academy of Sciences 2Unleashing the watchdog protein 2
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... and Bruker BioSpins Metabolic Profiler is ... and analysis of complex mixtures. It ... optional Avance NMR spectrometer and integrated ... statistical analysis for applications like:,Assessment of ...
Biology Products: